Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient

FDA Caution and Relabeling

Slide 4

November 2008

In July 2008, the FDA alert came about on a review of studies linking potentially fatal hypersensitivity reactions with abacavir in relations to a specific HLA-B allele (HLA-B*5701). Testing of HIV infected patients for this allele is recommended prior to prescribing Abacavir. This information is now added to the box warning and product label for this drug.

FDA Caution and Relabeling


Jump to section: